Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation.

Autor: da Cunha LP; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: lorenapcunha@yahoo.com.br., Silveira MN; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: marina.nogueira2@gmail.com., Mendes MCS; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: mariacarol.op@gmail.com., Costa FO; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: focca@fcm.unicamp.br., Macedo LT; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: ligiamed@gmail.com., de Siqueira NS; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: nadiascle@gmail.com., Carvalheira JBC; Division of Oncology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), MA: 13083-970, Campinas, São Paulo, Brazil. Electronic address: jbcc@g.unicamp.br.
Jazyk: angličtina
Zdroj: Clinical nutrition ESPEN [Clin Nutr ESPEN] 2019 Aug; Vol. 32, pp. 107-112. Date of Electronic Publication: 2019 Apr 16.
DOI: 10.1016/j.clnesp.2019.04.004
Abstrakt: Background & Aims: Sarcopenia has been associated with poor prognosis in a number of malignancies. However, whether sarcopenia is associated with colorectal cancer (CRC) prognosis in a metastatic setting remains unclear. The aim of the study presented was to evaluate the impact of sarcopenia on progression-free survival (PFS) and overall survival (OS) in patients with metastatic CRC.
Methods: We retrospectively studied 72 patients with stage IV CRC treated at the University of Campinas between 2009 and 2015. Computed tomography images were analyzed to assess body composition. The Kaplan-Meier and multivariate Cox proportional hazards regression were used for survival analysis and to evaluate the influence of sarcopenia on PFS and OS.
Results: Median PFS for sarcopenic patients (n = 32) was 7.2 months, which was significantly different from non-sarcopenic patients (n = 40), which was 15.2 months (hazard ratio [HR]: 1.78; 95% confidence interval [CI], 1.00-3.14; P = 0.048). Sarcopenia was also a significant predictor of OS. Median OS for sarcopenic patients was 12.5 months versus 36.7 months for non-sarcopenic patients (HR: 1.86; 95% CI, 1.02-3.38; P = 0.043), after adjustment for number of metastatic lesions, metastasectomy, and performance status.
Conclusions: Sarcopenia was associated with worse CRC PFS and OS. These findings require prospective trials to validate this association.
(Copyright © 2019 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: